The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1369
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
Revised 10/26/11: In the clinical studies section for telaprevir, "among patients who had a previous relapse" was added to the REALIZE trial sentence.

Telaprevir (Incivek – Vertex) and boceprevir (Victrelis – Merck) have been approved by the FDA for oral use in combination with peginterferon and ribavirin for treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults with compensated liver disease. Both telaprevir and boceprevir were developed specifically to inhibit the NS3/4A proteases that cleave HCV encoded polyproteins of the genotype 1 virus.

STANDARD THERAPY — Peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) plus oral ribavirin (Rebetol, Copegus, and others) have been the drugs of choice for treatment of chronic HCV infection.1 They produce sustained virologic responses (SVRs) – undetectable plasma HCV RNA 24 weeks after cessation of therapy – in 40-50% of patients with genotype 1 HCV infection. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1369
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian